Skip to main content

Cancer and Chemotherapy

Over the past 20 years, there has been significant progress in the treatment of cancer. The use of chemotherapy increases gradually and the specialists agree that chemotherapy will continue to be included in the treatment.

The use of chemotherapy increases which also render an increase of   complications. Chemotherapy can cause permanent nerve damage, including Chemotherapy Induced Peripheral Neuropathy (CIPN). This is especially true for colorectal, breast and lung cancer.

In Northwest Europe, chemotherapy is estimated to cause about 66,000 cases of CIPN every year whereof breast cancer account for the highest proportion. According to a US study the treatment cost due to CIPN was between $ 90 to $ 9,000 depending on the severity, caregiver and country (1).

Clinical Benefit – Oncology

For cancer treatment the VibroSense Meter II (VSM II) is intended for clinics in specialist care and researchers who work with treatments that can cause Chemotherapy Induced Peripheral Neuropathy (CIPN) in the hands and feet. The clinical benefit of VSM II is to support diagnosis and adjustment of treatment to mitigate the presence of CIPN .

The Target Profile for VSM II within chemotherapy is:

Target group

Clinical targets

Clinical use

Doctors, nurses and patients within treatment of cancer with chemotherapy having a risk of causing nerve damage.

Examination of foot or hand before (baseline) and after every chemotherapy treatment

*PCM: Personalized Cancer Medicine 
**CIPN: Chemotherapy Induced Peripheral Neuropathy